Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ONCY Stock Forecast 2026-2027
$1.11
Current Price
$130.06M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ONCY Price Targets
+809.3%
To High Target of $10.09
+290.5%
To Median Target of $4.33
+166.4%
To Low Target of $2.96
ONCY Price Momentum
+0.9%
1 Week Change
+16.8%
1 Month Change
+85.0%
1 Year Change
+27.6%
Year-to-Date Change
-26.5%
From 52W High of $1.51
+236.4%
From 52W Low of $0.33
📊 TOP ANALYST CALLS
Did ONCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Oncolytics Biotech is one of their latest high-conviction picks.
Latest ONCY Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, ONCY has a bullish consensus with a median price target of $4.33 (ranging from $2.96 to $10.09). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $1.11, the median forecast implies a 290.5% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ONCY Analyst Ratings
5
Buy
1
Hold
0
Sell
ONCY Price Target Range
Low
$2.96
Average
$4.33
High
$10.09
Current: $1.11
Latest ONCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ONCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $10.00 |
| Aug 13, 2025 | Lake Street | Chad Messer | Buy | Initiates | $7.00 |
| May 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 16, 2025 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Mar 10, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Mar 10, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $5.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Apr 4, 2024 | Raymond James | Rahul Sarugaser | Outperform | Initiates | $3.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jun 29, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
Oncolytics Biotech Inc. (ONCY) Competitors
The following stocks are similar to Oncolytics Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ONCY
Oncolytics
mkt cap
130.06M
Oncolytics Biotech Inc. (ONCY) Financial Data
Valuation Metrics
Market Cap
$130.06M
Enterprise Value
$125.42M
P/E Ratio
N/A
PEG Ratio
-4.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+4.1%
Current Ratio
1.1x
Debt/Equity
-0.1x
ROE
+757.0%
ROA
-171.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Oncolytics Biotech Inc. (ONCY) Business Model
About Oncolytics Biotech Inc.
What They Do
Develops immunotherapy for cancer treatment.
Business Model
The company focuses on developing pelareorep, an immunotherapy that targets cancer cells by inducing tumor lysis and enhancing immune responses. It generates revenue through partnerships with academic and pharmaceutical collaborators while advancing its clinical pipelines to address various solid tumors and hematological malignancies.
Additional Information
Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics Biotech Inc. aims to transform resistant tumors into responsive ones, potentially improving the efficacy of existing cancer treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Jared Kelly J.D., L.L.M.
Country
Canada
IPO Year
2018
Website
oncolyticsbiotech.comOncolytics Biotech Inc. (ONCY) Latest News & Analysis
Latest News
Quick Summary
Oncolytics Biotech (Nasdaq: ONCY) will meet with the FDA on April 16, 2026, to discuss a potential pivotal study for pelareorep in treating squamous cell anal carcinoma.
Why It Matters
The FDA meeting could signal progress for Oncolytics' drug, potentially increasing its market value and attracting investor interest in the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech Inc. has completed its relocation from Alberta, Canada, to Nevada, USA, with a new headquarters in San Diego, while maintaining its Calgary office.
Why It Matters
Oncolytics' move to Nevada may enhance its regulatory environment and access to U.S. capital markets, potentially boosting investor confidence and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech announced that pelareorep shows potential to enhance immune response in RAS-driven tumors, with increased response rates in breast and gastrointestinal cancers. Two abstracts will be presented at AACR 2026.
Why It Matters
Pelareorep's promising data in boosting response rates for RAS-driven tumors could enhance Oncolytics Biotech's market position and attract investment interest in immunotherapy advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech initiated a Phase 2 study for pelareorep in second-line KRAS-mutant MSS metastatic colorectal cancer, with preliminary data expected by late 2026. The treatment received Fast Track Designation.
Why It Matters
The Fast Track Designation and Phase 2 study for pelareorep in a significant cancer indication could accelerate its market entry, enhancing Oncolytics’ growth potential and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
1 month ago
Quick Summary
Oncolytics Biotech is winding down its GOBLET study to concentrate on U.S. registration for treatments in SCAC and CRC, with enough cash to meet near-term milestones and avoid dilution.
Why It Matters
Oncolytics Biotech is shifting focus to registration studies, signaling a strategic pivot that may enhance its market position and potential for future revenue, while avoiding immediate dilution.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A treatment shows a 33% overall response rate, 16.6 months progression-free survival, and 27 months overall survival, outperforming standard of care by 2-3 times in a challenging patient group.
Why It Matters
Strong efficacy signals indicate a significant advancement over standard of care, potentially leading to increased market share and revenue for the company, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ONCY Stock
What is Oncolytics Biotech Inc.'s (ONCY) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Oncolytics Biotech Inc. (ONCY) has a median price target of $4.33. The highest price target is $10.09 and the lowest is $2.96.
Is ONCY stock a good investment in 2026?
According to current analyst ratings, ONCY has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ONCY stock?
Wall Street analysts predict ONCY stock could reach $4.33 in the next 12 months. This represents a 290.5% increase from the current price of $1.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oncolytics Biotech Inc.'s business model?
The company focuses on developing pelareorep, an immunotherapy that targets cancer cells by inducing tumor lysis and enhancing immune responses. It generates revenue through partnerships with academic and pharmaceutical collaborators while advancing its clinical pipelines to address various solid tumors and hematological malignancies.
What is the highest forecasted price for ONCY Oncolytics Biotech Inc.?
The highest price target for ONCY is $10.09 from at , which represents a 809.3% increase from the current price of $1.11.
What is the lowest forecasted price for ONCY Oncolytics Biotech Inc.?
The lowest price target for ONCY is $2.96 from at , which represents a 166.4% increase from the current price of $1.11.
What is the overall ONCY consensus from analysts for Oncolytics Biotech Inc.?
The overall analyst consensus for ONCY is bullish. Out of 9 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.33.
How accurate are ONCY stock price projections?
Stock price projections, including those for Oncolytics Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 11:01 PM UTC